Business
We are leveraging our novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Humacyte, Inc.: Revenue grew to $2.038M from $0. Net loss narrowed to $40.83M from $149M. Free cash flow outflow widened to $106M from $99.69M. Operating margin was -5306.04%. Humacyte, Inc.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew to $2.038M from $0OK
- Profitability — Net loss narrowed to $40.83M from $149MOK
- Cash flow — Free cash flow outflow widened to $106M from $99.69MWatch
- Margins — Operating margin was -5306.04%Note
- Accounting — Going-concern warningWatch
- Insiders — 0 purchases and 6 salesWatch
Where the revenue comes from
Fiscal 2025, as Humacyte, Inc. reports it. History and quarterly detail are in the app.
- Product$1.4M
- Product And Service Other$649K
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-31
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Humacyte, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.